With sales of Acomplia (rimonabant) lagging in the several dozen countries where it is on the market, a major unanswered question is whether enthusiasm for the diet drug is fading — or whether internet sites marketing various generic versions of rimonabant are impacting sales of Acomplia.
Sanofi reported that fourth quarter sales of Acomplia worldwide totaled 21 million Euros (approximately US $30.6 million) so the fact is that sales of the diet pill are not growing.Indian pharmaceutical companies marketing versions of Rimonabant Acomplia under a variety of brand names also have not reported sales figures, so it is difficult to assess their impact on Acomplia.
The problem with this generic acomplia rimonabant is not for people,is for Sanofi,because this generic acomplia is very safe and it is no danger in buying it.But the problem is that is cheaper that Acomplia by Sanofi.
So the problem is this way:You get the same effect but you pay less if you buy Rimonabant Acomplia generic.Instead, Sanofi unveiled plans to make at least three presentations at major U.S. and European medical meetings during 2008 on the results of clinical trials of Acomplia as a treatment for heart disease and diabetes.
And as a strong indication that the results Sanofi is seeing from the diabetes trials continue to look positive, the French pharmaceutical company reiterated that it plans to once again seek FDA approval of rimonabant (to be called Zimulti in the United States), this time for treatment of diabetes, in 2009. Cluzel said Sanofi would be making a presentation in April 2008 to the European Atherosclerosis Society on its ADAGIO trial, evaluating rimonabant in patients with dyslipidemia.
Dyslipidemia is elevation of plasma cholesterol or a low HDL level that contributes to development of atherosclerosis. He said results of the ARPEGGIO study, evaluating rimonabant in combination with insulin for treatment of diabetes, will be presented to the American Diabetes Association at its annual meeting in June 2008. Cluzel also said Sanofi is awaiting further recommendations from the FDA on the tracking during clinical trials of depressive side-effects associated with rimonabant — the problem that led in mid-2007 to Sanofi’s withdrawal of its application to have Acomplia approved for sale as an obesity drug in the U.S.
Buy Rimonabant Acomplia
Leave a Comment